

Vector Neurosciences LLC Offers Second Set of Assets Formerly Owned by Neurologix, Inc. for Sale at a Public Auction To Be Held in New Jersey

A second set of assets from the Neurologix Bankruptcy is being sold.

WELLESLEY HILLS, Mass. ([PRWEB](#)) May 27, 2016 -- Joseph F. Finn, Jr. C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP ("FWG"), announced today that Vector Neurosciences LLC of Livingston, NJ ("Vector") has retained FWG to offer for sale certain patents, patent applications and related intellectual property formerly owned by Neurologix, Inc. ("Neurologix") in which Vector possesses a security interest. Vector recently acquired rights to the patents, patent applications and the related intellectual property from the senior lenders and noteholders of Neurologix, which Vector will offer for sale at a public auction to be held on Wednesday July 13, 2016 at 10:00 a.m. at the offices of McCarter & English, LLP, 100 Mulberry Street, Four Gateway Center, Newark, New Jersey. Vector reserves the right to credit bid on the patents, patent applications and related intellectual property up to the amount of \$9,908,559.22.

The Neurologix assets offered for sale include all of its right, title and interest in and to the patents, patent applications and related intellectual property described below that cover glutamic acid decarboxylase (GAD) based delivery systems for treating neurodegenerative diseases.

The sale assets are jointly owned by Neurologix Inc. and Thomas Jefferson University, and the auction will only include the right, title and interest of Neurologix in and to such patents, patent applications and related intellectual property. The right, title and interest of Thomas Jefferson University in and to the sale assets are not included in the auction. By serial number, the patents include US 6,780,409, US 7,645,446, US 7,695,959, US 7,955,595, AU 2001268080, CA 2,409,674, EP 1299126, and DE 60106763. By serial number, the patent applications include US 60/206,281, PCT/US01/16592 and US 13/095,273.

Persons interested in bidding must sign a Non-Disclosure Agreement ("NDA") before receiving a bid package. The NDA may be obtained by contacting FWG – [IPSaleServices\(at\)finnwarnkegayton\(dot\)com](mailto:IPSaleServices(at)finnwarnkegayton(dot)com) or (781) 237 – 8840. Bid packages including more specific information on the patents, patent applications and related intellectual property (including any corresponding foreign issued patents) being offered for sale will be provided by email upon receipt of an executed NDA.

About Finn, Warnke & Gayton, LLP:

Joseph F. Finn, Jr. C.P.A., is the founding partner of Finn, Warnke & Gayton, LLP (www.finnwarnkegayton.com) Certified Public Accountants of Wellesley Hills, Massachusetts.

FWG has liquidated a number of patent portfolios specific to CNS, and gene therapies.

For further information, please contact Joseph F. Finn, Jr. C.P.A. at (781) 237 – 8840 or [jffinnjr\(at\)finnwarnkegayton\(dot\)com](mailto:jffinnjr(at)finnwarnkegayton(dot)com).
SOURCE Joseph F. Finn, Jr. C.P.A.

**Contact Information****Chris Finn**

Finn Warnke & Gayton

<http://www.finnwarnkegayton.com>

+1 (781) 237-8840

Online Web 2.0 VersionYou can read the online version of this press release [here](#).